Open AccessAn Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
Author(s) -
Giannis Mountzios,
Sofia Lampaki,
Georgia-Angeliki Koliou,
Athanassios Vozikis,
Ioannis Kontogiorgos,
Panagiotis Papantoniou,
Margarita-Ioanna Koufaki,
Eleni Res,
Anastasios Boutis,
Athina Christopoulou,
Nicoleta Pastelli,
Anastasios Grivas,
Gerasimos Aravantinos,
Efthalia Lalla,
Georgios Oikonomopoulos,
Anna Koumarianou,
Dionisios Spyratos,
Dimitrios Bafaloukos,
Georgios Rigakos,
Pavlos Papakotoulas,
George Fountzilas,
Helena Linardou
Publication year - 2021
Publication title -
lung cancer
Language(s) - English
Resource type - Journals
ISSN - 1179-2728
DOI - 10.2147/lctt.s318007
Subject(s) - afatinib , medicine , oncology , epidermal growth factor receptor , lung cancer , retrospective cohort study , epidemiology , observational study , medical record , cancer , gefitinib
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, has been extensively used in Greece in this setting; however, real-world data regarding molecular epidemiology and financial implications of afatinib use are lacking.